Zacks: Brokerages Anticipate Pacira BioSciences, Inc. (NASDAQ:PCRX) Will Announce Earnings of $0.91 Per Share

Equities analysts predict that Pacira BioSciences, Inc. (NASDAQ:PCRXGet Rating) will announce earnings per share of $0.91 for the current quarter, according to Zacks. Six analysts have issued estimates for Pacira BioSciences’ earnings, with the lowest EPS estimate coming in at $0.78 and the highest estimate coming in at $1.04. Pacira BioSciences reported earnings of $0.77 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 18.2%. The firm is expected to report its next earnings results on Monday, January 1st.

On average, analysts expect that Pacira BioSciences will report full-year earnings of $3.89 per share for the current fiscal year, with EPS estimates ranging from $3.42 to $4.48. For the next fiscal year, analysts expect that the firm will report earnings of $5.21 per share, with EPS estimates ranging from $4.14 to $5.98. Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Pacira BioSciences.

Pacira BioSciences (NASDAQ:PCRXGet Rating) last posted its quarterly earnings results on Wednesday, May 4th. The company reported $0.64 earnings per share for the quarter, missing the consensus estimate of $0.83 by ($0.19). The business had revenue of $157.99 million during the quarter, compared to analysts’ expectations of $155.08 million. Pacira BioSciences had a return on equity of 15.17% and a net margin of 6.62%. The business’s quarterly revenue was up 32.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.37 earnings per share.

A number of equities analysts have commented on PCRX shares. HC Wainwright lifted their target price on shares of Pacira BioSciences from $86.00 to $90.00 and gave the stock a “buy” rating in a research note on Friday, February 25th. StockNews.com started coverage on shares of Pacira BioSciences in a research note on Thursday, March 31st. They set a “hold” rating on the stock. Northland Securities lifted their target price on shares of Pacira BioSciences from $61.00 to $67.00 in a research note on Tuesday, March 1st. Wedbush reaffirmed a “buy” rating and set a $94.00 target price (down from $97.00) on shares of Pacira BioSciences in a research note on Saturday, February 26th. Finally, TheStreet downgraded shares of Pacira BioSciences from a “b-” rating to a “c” rating in a research note on Thursday, February 24th. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $80.63.

Shares of NASDAQ:PCRX traded up $0.55 during midday trading on Friday, hitting $63.59. The company’s stock had a trading volume of 351,717 shares, compared to its average volume of 541,323. The business’s 50 day simple moving average is $71.88 and its 200 day simple moving average is $64.84. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.85 and a current ratio of 2.19. The company has a market cap of $2.89 billion, a P/E ratio of 75.70 and a beta of 0.88. Pacira BioSciences has a 12-month low of $45.05 and a 12-month high of $82.16.

In other Pacira BioSciences news, Director Mark Froimson sold 1,000 shares of the company’s stock in a transaction on Monday, May 9th. The stock was sold at an average price of $59.37, for a total transaction of $59,370.00. Following the transaction, the director now directly owns 4,908 shares in the company, valued at $291,387.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Anthony Molloy sold 22,500 shares of the company’s stock in a transaction on Wednesday, April 6th. The stock was sold at an average price of $76.42, for a total value of $1,719,450.00. Following the transaction, the insider now owns 17,550 shares in the company, valued at $1,341,171. The disclosure for this sale can be found here. Insiders have sold 69,607 shares of company stock worth $5,092,865 over the last 90 days. 5.20% of the stock is owned by insiders.

A number of large investors have recently added to or reduced their stakes in PCRX. Van Hulzen Asset Management LLC raised its stake in shares of Pacira BioSciences by 1.4% in the first quarter. Van Hulzen Asset Management LLC now owns 12,742 shares of the company’s stock valued at $972,000 after acquiring an additional 178 shares in the last quarter. Walleye Capital LLC raised its stake in shares of Pacira BioSciences by 17.3% in the first quarter. Walleye Capital LLC now owns 135,027 shares of the company’s stock valued at $10,305,000 after acquiring an additional 19,930 shares in the last quarter. Avalon Investment & Advisory acquired a new stake in shares of Pacira BioSciences in the first quarter valued at $3,592,000. Point72 Hong Kong Ltd raised its stake in shares of Pacira BioSciences by 99.9% in the first quarter. Point72 Hong Kong Ltd now owns 3,494 shares of the company’s stock valued at $267,000 after acquiring an additional 1,746 shares in the last quarter. Finally, Royal Bank of Canada raised its stake in shares of Pacira BioSciences by 63.9% in the first quarter. Royal Bank of Canada now owns 34,748 shares of the company’s stock valued at $2,653,000 after acquiring an additional 13,542 shares in the last quarter.

About Pacira BioSciences (Get Rating)

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves.

See Also

Get a free copy of the Zacks research report on Pacira BioSciences (PCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pacira BioSciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.